Manuel Pérez-Encinas

17PUBLICATIONS
102CO-AUTHORS
Medical infection agents (incl. prions)Haematological tumoursMolecular targetsCardiology (incl. cardiovascular diseases)Respiratory diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Aug 31, 2026
Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: The PETHRATIFY Study.

|Aug 04, 2026
Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era.

|Jul 14, 2023
Presence of Myeloid Mutations in Patients with Chronic Myeloid Leukemia Increases Risk of Cardiovascular Event on Tyrosine Kinase Inhibitor Treatment.

Ruth Stuckey, Adrián Segura-Díaz, María Nieves Sáez Perdomo

|Feb 25, 2023
Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors.

Lucía Pérez-Lamas, Alejandro Luna, Concepción Boque

|Nov 14, 2022
CNL and aCML should be considered as a single entity based on molecular profiles and outcomes.

Gonzalo Carreño-Tarragona, Alberto Álvarez-Larrán, Claire Harrison

|Jun 10, 2022
Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia.

David Martínez-Cuadrón, Josefina Serrano, José Mariz

Pageof 3

Frequent Collaborators

5 joint publications

David Martínez-Cuadrón

5 joint publications

Miguel-Ángel Sanz

5 joint publications

Juan-Carlos Hernández-Boluda

4 joint publications

Ruth Stuckey